A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice.
A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice.
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related comorbidity.
The study will last up to 12 months.
Inclusion Criteria:
Exclusion Criteria:
LillyTrials@Lilly.com1-317-615-4559
clinical_inquiry_hub@lilly.com
Avondale, Arizona 85392, United States
602-386-4971
Chandler, Arizona 85225, United States
Flagstaff, Arizona 86001, United States
Gilbert, Arizona 85297, United States
Glendale, Arizona 85306, United States
Mesa, Arizona 85210, United States
Phoenix, Arizona 85032, United States
Sun City, Arizona 85351, United States
Tucson, Arizona 85704, United States
Tucson, Arizona 85748, United States
Saint Clair Shores, Michigan 48081, United States
Salisbury, North Carolina 28144, United States
Murfreesboro, Tennessee 37128, United States
Colleyville, Texas 76034, United States
Fort Worth, Texas 76109, United States
Irving, Texas 75039, United States
480-443-8400
928-666-3772
480-443-8400
602-386-4969
480-626-6637
480-626-6637
602-386-4970
520-867-6906
520-849-8753
909-581-8477
626-869-5730
714-378-2440
619-229-1995 x208
(951) 672-1866
9516525000
8182652250
5627586600
5615591110
7703723962
9125480710
7732753500
8475992492
4349628466
5024953665
337-312-8018
301-724-4337
301-791-6680
406-752-2010
800-785-3150
440-826-0742
731-633-0145
480-626-6650
9722998399
817-789-6770
281-481-8557
281-944-3610
(281) 944-3610
936-681-4882
281-517-0550
939-599-0382